Klin Onkol 2008; 21(3): 110-115.
Backgrounds: This authors team has been dealing with the Hodgkin disease problems since 1971. The MORHO study started at eight working places in 1978 according to unifi ed diagnostic and medical protocol. Patients and methods: 370 patients were treated. The treatment consisted in the combination of radiation and chemotherapy COPP and since 1988 in alternance of COPP and ABVD. Therapy was modifi cated with accordance to clinical stages and patient´s histological type and age. Treatment of the patients over 50 was reduced in decades of one chemotherapy cycle less. Results: Results from the clinical study are – patients with the stage IIA, IIB and IIIA survive 30 years in 59,29%, 57,86% and 60,72%. Patients diagnosed as stage IIIB survive after 30 years 36,78%, while patients in stages IVA and IVB survived 10 years 24,51% and 23,32% and 20 years 8,61% in stage IVB. Women survived longer than men. Histological types had no infl uence to the lenght of survival. The total number of relapses in the group was 55. There were 39 men and 16 women from that. 64% was in stage III and IV and in 73% mediastinal nodules were affected. 42% of relapses was till 1 year after the treatment. After the treatment 75 children were born to the patients from the group. 60 children from that were born to the women under treatment. Conclusion: The success of therapy of Hodgkin´s disease according to protocol created by expert group of study MORHO is comparable with results of similar studies in the world. The most important contribution of this study was unifi cation of treatment protocol in Czechoslovakia. This study changed the formerly paliative therapy to real curative treatment.
